Related Experiment Video
Updated: Sep 19, 2026

Small Bowel Transplantation In Mice
Published on: August 20, 2007
Successful Early Therapy With Sirolimus for an Infant With Primary Intestinal Lymphangiectasia
Shungo Yamamoto1, Yoshihiko Sugino1, Takahiro Yamashita1
1Department of Pediatrics, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan, jrc.or.jp.
Introduction:
Identifying the cause of protein-losing enteropathy (PLE) is crucial for appropriate treatment. Primary intestinal lymphangiectasia (PIL) is a cause of PLE, and low-strict fat diet with medium-chain triglyceride (MCT) supplementation may be insufficient. Sirolimus has shown efficacy in refractory PIL; however, its use in infants remains uncommon, and the optimal timing of initiation has not been established.
Case Presentation:
A previously healthy 7-month-old Japanese male infant presented with convulsions, generalized edema, and diarrhea. Laboratory findings revealed severe hypoproteinemia (serum albumin: 1.3 g/dL), lymphopenia (absolute lymphocyte count: 822/μL), and electrolyte abnormalities. Scintigraphy using 99mTc-labeled human serum albumin showed tracer exudate in the small intestine, leading to the diagnosis of PLE. Upper endoscopy revealed snowflake-like white spots in the duodenum, and pathological examination confirmed lymphatic dilation, leading to a PIL diagnosis. Despite treatment with a low-strict fat diet with MCT supplementation and corticosteroids, hypoproteinemia persisted. Lymphatic scintigraphy and magnetic resonance lymphangiography confirmed ongoing protein leakage. Sirolimus was initiated at 0.5 mg/day on Day 23. Subsequently, serum albumin began to increase within 1-2 weeks and ultimately reached 4.1 g/dL, and absolute lymphocyte count, 1917/μL immediately before sirolimus initiation, increased to 3843/μL. Lymphatic scintigraphy on Day 74 of sirolimus treatment showed complete resolution of protein leakage. Sirolimus was continued for 121 days and discontinued thereafter. At 17 months of follow-up, no recurrence was observed, with sustained normalization of serum albumin to 4.0 g/dL and absolute lymphocyte count to 4739/μL.
Discussion:
This case suggests one of the earliest reported responses to sirolimus in the treatment of PIL, with improvement observed within a few weeks of initiation. Early introduction of sirolimus in patients with persistent protein leakage resistant to low-strict fat diet with MCT supplementation may be associated with rapid improvement in PIL, though this hypothesis warrants further case accumulation.
